ClinicalTrials.gg
RecruitingNCT05745857SLURPUpdated Apr 13, 2026

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

A Phase 2 interventional study of Avastin and Erbitux in Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia and Esophageal Adenocarcinoma, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by University Medical Center Groningen · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands — 11 open to participants now, 16 under way, 3 of them phase 3. Adenocarcinoma Of Esophagus · Netherlands.

Planned enrollment
14th of 17
25 · median 195
Started
2023
with 4 others
Phase 2
7 of 25
4 open now
Primary completion
2026-05
later than 4 of 15 live
Registered
16th of 25
by date
Lead sponsor
2 of 25
University Medical Center Groningen

Among the 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands, this one is the 14th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2023, is one of 7 in phase 2, reaches primary completion later than 4 of the 15 other live ones, and was the 16th registered.

Adenocarcinoma Of Esophagus

353 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

11 of the 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Adenocarcinoma Of Esophagus with a site in Netherlands, or all of them as a file.
02

Study summary

Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.

Read the detailed description

However, the investigators hypothesized, that additional lesions can potentially be identified by simultaneous use of two targeted tracers because of variable expression of vascular endothelial growth factor A (VEGFA) and epidermal growth factor receptor (EGFR )within oesophageal adenocarcinoma (EAC). Until now, solely intravenous and topical administration of the tracers has been investigated. However, optimization of tracer administration and shortened incubation is necessary for clinical translation and implementation of this new technique from Barrett's esophagus (BE) expert centers to regional non-expert centers. BE surveillance procedures normally takes up to 15 minutes at regional hospitals, of which most of the procedural time is needed to take biopsies according to the Seattle protocol. Introducing qFME into these hospitals would elongate the procedure time with at least 10 - 15 minutes. This would increase healthcare costs and put increased pressure on BE healthcare. Ideally, the gastroenterologist can immediately start with the qFME procedure without any incubation time while maintaining the best target-to-background ratios (TBR) possible. Oral administration by drinking the tracer prior to the procedure would eliminate incubation time and its consequences. Quantified qFME with oral tracer administration and targeted biopsies could potentially replace the time-consuming, high miss rate Seattle protocol, improve lesion detection and decrease global healthcare costs associated with BE.

03

Conditions studied

  • Barrett's Esophagus Without Dysplasia
  • Barrett Oesophagitis With Dysplasia
  • Esophageal Adenocarcinoma

Keywords

  • Fluorescence molecular endoscopy
  • Spectroscopy
  • Barrett's esophagus
  • Esophageal adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BE patients without dysplasia and with suspected/diagnosed low-grade dysplasia (LGD), high-grade dysplasia (HGD) or superficial EAC and planned diagnostic and/or therapeutic endoscopy
  • Written is obtained

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of eighteen.
  • Submucosal and invasive EAC, also defined as EAC with tumor, node and (TNM)-classification other than T1.
  • Previous radiation therapy for esophageal cancer
  • Known immunoglobulin allergy
  • Previous chemotherapy, immunotherapy or related surgery
  • Prior bevacizumab or cetuximab treatment
  • Medical or psychiatric conditions that compromise the patient's ability to give
  • Pregnancy or breast feeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Oral bevacizumab-800CW

    Dose finding of oral bevacizumab-800CW and extend optimal dose group (n = 5 - 10)

    Drug: Avastin · Device: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

  • Experimental
    Oral cetuximab-800CW and combined oral cetuximab-800CW and bevacizumab-800CW

    Dose finding of oral cetuximab-800CW in first five patients and combined oral bevacizumab-800CW and cetuximab-800CW if the investigators see good results with cetuximab-800CW. If not, they will add a control group of non-dysplastic BE patients and administer oral bevacizumab-800CW. (n = 15)

    Drug: Avastin · Drug: Erbitux · Device: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

  • Experimental
    Combined topical tracer administration bevacizumab-800CW and cetuximab-800CW

    This arm will only be part of the study when oral administration is not feasible or safe. Compare single topical tracer administration of bevacizumab-800CW with combined topical tracer administration of bevacizumab-800CW and cetuximab-800CW. Extend combined group when lesion detection is increased or add control group with non-dysplastic BE patients if not. (n = 20)

    Drug: Avastin · Drug: Erbitux · Device: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

Interventions

  • DrugBevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Orally administered

    Also known as: Bevacizumab

  • DrugCetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Orally administered

    Also known as: Cetuximab

  • DeviceFluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

    Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope

06

What researchers measure

Primary outcomes

  1. Feasibility of shortening qFME procedural time by oral administration of bevacizumab-800CW and cetuximab-800CW for the detection of BE neoplasia.

    Evaluating the performance of qFME with oral administration of bevacizumab-800CW and cetuximab-800CW for detection of neoplasia in BE patients compared to HD-WLE. This comparison will be based on target-to-background rations calculated from the in vivo fluorescence images and quantified by MDSFR/SFF spectroscopy measurements

    Time frame: 12 months

  2. Evaluate if the combination of tracers improves lesion detection by the number of invisible lesions detected

    Increased lesion detection in % compared to previously gathered amount of invisible lesions with topical tracer administration

    Time frame: 12 months

Secondary outcomes

  1. Collect safety data on oral administration of (combined) bevacizumab-800CW and cetuximab-800CW.

    Blood pressure in millimeters of mercury (mmHg)

    Time frame: Five minutes before and ten minutes after tracer administration

  2. Heart rate

    Beats per minute

    Time frame: Five minutes before and ten minutes after tracer administration

  3. Temperature

    Degrees Celsius

    Time frame: Five minutes before and ten minutes after tracer administration

  4. To (semi)quantify and evaluate the in vivo fluorescent signal of bevacizumab-800CW and cetuximab-800CW

    Correlate and validate fluorescence signals detected in vivo with ex vivo histopathology grade of dysplasia and VEGFA and EGFR expression

    Time frame: 12 months

  5. Eventually further specify and objectify the improvement of qFME by standardisation

    Determining optimal pre-set features for gain and exposure times for our fluorescence camera system

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for May 2026, 32 months after the start.

Of 51 non-industry phase 2 interventional studies under Adenocarcinoma Of Esophagus, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 32 months is below that.

Counting every sponsor, half of 60 studies reached it within 55 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 27, 2023
StartActual
Sep 15, 2023
Primary completionEst.
May 2026
CompletionEst.
Dec 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05745857
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Sep 15, 2023
Primary completion
May 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Wouter B Nagengast, Prof. dr.
Contact
w.b.nagengast@umcg.nl
+31(0)503615755
Wouter B. Nagengast, Prof. dr.
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion